Bioventus
BVS

Bioventus (BVS) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Cantor FitzgeraldMaintainedOverweight$15.00Aug 17, 2026
Canaccord GenuityMaintainedBuy$19.00 from $15.00Aug 17, 2026
Barrington ResearchMaintainedOutperform$14.00Jun 30, 2026
Canaccord GenuityMaintainedBuy$15.00Jun 16, 2026
Barrington ResearchMaintainedOutperform$14.00May 22, 2026
Craig-HallumMaintainedBuy$16.00 from $15.00Mar 6, 2026
Barrington ResearchMaintainedOutperform$14.00 from $13.00Mar 6, 2026
Barrington ResearchInitiated CoverageOutperform$13.00Feb 9, 2026
Cantor FitzgeraldInitiated CoverageOverweight$12.00Jul 7, 2025
Canaccord GenuityMaintainedBuy$15.00Mar 17, 2025
JP MorganUpgradedUnderweight → Neutral$13.00 from $12.00Dec 17, 2024
Canaccord GenuityMaintainedBuy$15.00 from $12.00Nov 6, 2024
Craig-HallumMaintainedBuy$17.00 from $12.00Sep 27, 2024
Canaccord GenuityMaintainedBuy$12.00 from $8.00Aug 13, 2024
Craig-HallumMaintainedBuy$12.00 from $9.00Aug 7, 2024
Canaccord GenuityMaintainedBuy$8.00 from $7.00May 8, 2024
Craig-HallumMaintainedBuy$9.00 from $6.00Mar 13, 2024
Canaccord GenuityUpgradedHold → Buy$7.00 from $3.66Dec 7, 2023
Craig-HallumMaintainedHold$5.00 from $10.00Apr 3, 2023

Frequently asked questions

  • What is the latest analyst rating on BVS?

    On Aug 17, 2026, Cantor Fitzgerald maintained Bioventus at Overweight with a price target of $15.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.